Latest News and Updates from PORTON - Your Trusted CDMO Partner

CN
Newsroom


A Customer-centric, Innovative
and Reliable CDMO with Global Solutions

1-21 of 184 result

News Jan 14, 2025

Successful GMP Drug Product Delivery by Porton Biologics and Conjugates Platform

Recently, the Porton Biologics and Conjugates Platform successfully completed the GMP contract manufacturing of three batches of sterile drug products for a client at our R&D and production facility in Pudong, Shanghai. This milestone marks a significant step forward for our Biologics and Conjugates CDMO platform—a testament to our unwavering commitment to quality and reliability.

News Jan 03, 2025

Porton Achieves Higher Scores in the 2024 S & P Global ESG Assessment

Porton Pharma Solutions Ltd. (hereinafter “Porton”) is glad to announce that it scored 44 (out of 100) in the 2024 S&P Global Corporate Sustainability Assessment reflecting an improvement of 6 points over the previous assessment, where scores in all the three dimensions getting improved. (CSA Score as of 27/11/2024).

Porton and Dragon Sail Pharmaceutical Form Strategic Partnership

News Dec 23, 2024

Porton Pharma Solutions and Dragon Sail Pharmaceutical Form Strategic Partnership

On December 20, 2024, Porton Pharma Solutions Ltd. (hereinafter referred to as “Porton Pharma Solutions” or “Porton”) and Dragon Sail Pharmaceutical (Shanghai) Co., Ltd. (a subsidiary of Guilin Sanjin, hereinafter referred to as “Dragon Sail Pharmaceutical”) formally signed a strategic cooperation agreement in Guilin, southern of China.

Porton Newsletter | Q4 2024 Recap

NewslettersDec 19, 2024

Porton Newsletter | Q4 2024 Recap

Porton Expands GMP Manufacturing and New Modality Services in Shanghai Fengxian Porton Successfully Hosts Ceremony for New Modality Capacity Upgrade Drug Modalities: Innovative Services & Solutions from Porton Pharma

Porton and Aojin Collaborate to Advance XDC Drugs for Dual INDs in China and U.S.

News Dec 11, 2024

Porton and Aojin Collaborate to Advance XDC Drugs for Dual INDs

Recently, Porton Pharma Solutions Ltd. ("Porton") announced a strategic partnership with Aojin Life Sciences (Yixing) Co., Ltd. ("Aojin Life Sciences").

Porton shuitu Site block

News Dec 06, 2024

Porton Recognized as an Exemplary Case for Sustainable Development

Porton was recently selected as a "2024 Exemplary Case for Sustainable Development Among Chinese Listed Companies" by the China Association of Public Companies.

Porton's newly redesigned website

News Dec 06, 2024

Porton is thrilled to announce the launch of its newly redesigned official website

With a Focus on Globalization, Innovative Technology Platforms, and Accelerating Your New Business Opportunities into the Clinic and to the Market.

News Nov 13, 2024

Porton Has Been Invited to the China–Slovenia Business and Investment Forum

During the Slovenian government delegation's visit to Shanghai, the Slovenian Consulate in Shanghai and the Shanghai Municipal Commission for Trade Promotion hosted the "China–Slovenia Business and Investment Forum" on November 4th, 2024.

News Nov 09, 2024

Porton’s New Modality Capacity Upgrade Ceremony Successfully Held

On November 7, 2024, the New Modality Capacity Upgrade Ceremony was successfully held in Fengxian, Shanghai, China. Attendees included Mr. Weng Jun,Vice General Manager,Shanghai Hangzhou Bay Economic & Technological Development Co., Ltd., Mr. Bai Yinchun, COO and Senior Vice President of Porton, Ms. Pi Wei, Vice President and Board Secretary of Porton, Ms. Meng Fan, Deputy General Manager of the Sales & Marketing Center of Porton, and Mr. Xie Lihua, Head of the Synthetic Macromolecules Service Department. Together, they witnessed this significant moment of enhancing the production capacity for new modalities at the Fengxian site.

Become part of Porton' s community to access personalized insights and resources.
Subscribe To Our Mailing List
Porton requires your contact information to reach out to you about our products and services. You can unsubscribe from these communications at any time. For details on how to unsubscribe and our commitment to protecting your privacy, please review ourLegal Disclaimer terms and Porton Privacy.

ⓒ 2024 PORTON Legal Notices | Porton Privacy

This website provides information on products tailored for a diverse audience and may include product details or information that are not readily accessible or valid in your country. Please note that we do not accept any responsibility for accessing such information in a manner that may violate any legal processes, regulations, registrations, or usage guidelines in your country of origin.

Become part of Porton' s community to access personalized insights and resources.
Submit
By clicking “Submit” you agree to our Legal Disclaimer terms and conditions and the Porton Privacy and Cookies Policy.

ⓒ 2024 PORTON Legal Notices | Porton Privacy

US: (609) 860-1300
CN: (86) 23-8608-3200